FDA Approves First Drug for Fourth-Line Treatment of Advanced Gastrointestinal Stromal Tumors
SILVER SPRING, Md., May 15, 2020 /PRNewswire/ --Today, the U.S. Food and Drug Administration approved Qinlock (ripretinib) tablets as the first new drug specifically approved as a fourth-line treatment for advanced gastrointestinal stromal tumor (GIST), a type of tumor that originates in the gastrointestinal tract.
- SILVER SPRING, Md., May 15, 2020 /PRNewswire/ --Today, the U.S. Food and Drug Administration approved Qinlock (ripretinib) tablets as the first new drug specifically approved as a fourth-line treatment for advanced gastrointestinal stromal tumor (GIST), a type of tumor that originates in the gastrointestinal tract.
- Qinlock is indicated for adult patients who have received prior treatment with three or more kinase inhibitor therapies, including imatinib.
- GISTs arise when abnormal cells form in the tissues of the gastrointestinal tract.
- GISTs most commonly occur in the stomach, small intestine, and large intestine but can start anywhere along the gastrointestinal tract.